
Biotricity Announces Key Patent Filing for Biotres Electrocardiogram (ECG) Wearable Device
Biotricity, Inc. (NASDAQ: BTCY), a device manufacturer in the Technology-as-a-Service (TaaS) sector specializing in remote cardiac monitoring in consumer healthcare announced the filing of a key patent application for its Biotres device.
The core innovation safeguarded by this patent is Biotres’ proprietary 3-channel technology, integrated with multiple sensors and housed in a compact form factor. This combination, addresses a critical limitation in compact cardiac monitoring devices, which often lacked the ability to capture multiple channels, thus compromising the quality of diagnoses. Biotricity stated that it anticipates filing two more patents within the next year, building upon its existing portfolio.
Biotres is a compact 3-channel connected cardiac monitor that offers multiple ECG channels, a range of sensors, rechargeability, and seamless connectivity within a compact patch form factor. With a recording capacity of up to 30 days, Biotres empowers patients and healthcare providers with continuous monitoring, while its wireless connectivity streamlines data offloading and remote ECG access, significantly reducing result wait times from weeks to just three days or less. Physicians can remotely access ECG data, and patients can report symptoms via an intuitive app, ensuring faster clinician response.
Dr. Waqaas Al-Siddiq, the CEO of Biotricity, expressed his enthusiasm for this milestone, stating, “This filing is part of our broader strategy of continually expanding our IP portfolio with trade secrets and patents. As we consistently innovate and expand our IP and FDA 510(k) portfolios, we are not only winning market share and protecting our IP but continuously increasing the barriers to entry.”